TELA Bio Closes $34.5M Public Offering
Ticker: TELA · Form: 8-K · Filed: May 20, 2024 · CIK: 1561921
| Field | Detail |
|---|---|
| Company | Tela Bio, Inc. (TELA) |
| Form Type | 8-K |
| Filed Date | May 20, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: financing, public-offering, medical-devices
TL;DR
TELA Bio just closed a $34.5M stock offering to fund operations. Bullish.
AI Summary
On May 19, 2024, TELA Bio, Inc. filed an 8-K report to announce the closing of its previously announced underwritten public offering. The company successfully raised approximately $34.5 million in gross proceeds before deducting underwriting discounts and commissions and other offering expenses. TELA Bio intends to use the net proceeds for general corporate purposes, including research and development, sales and marketing, and working capital.
Why It Matters
This capital raise provides TELA Bio with additional funds to support its ongoing operations and strategic initiatives, potentially enabling further growth and product development in the surgical and medical instruments sector.
Risk Assessment
Risk Level: medium — While the capital raise is positive, the company operates in a competitive medical device market and its success depends on continued innovation and market adoption.
Key Numbers
- $34.5M — Gross Proceeds (Raised from public offering to fund general corporate purposes.)
- May 19, 2024 — Offering Closing Date (Date of the earliest event reported in the 8-K.)
Key Players & Entities
- TELA Bio, Inc. (company) — Registrant
- May 19, 2024 (date) — Date of earliest event reported
- $34.5 million (dollar_amount) — Gross proceeds from public offering
- Delaware (jurisdiction) — State of incorporation
- Malvern, Pennsylvania (location) — Principal executive offices
FAQ
What was the total amount raised in the public offering?
The company raised approximately $34.5 million in gross proceeds.
What is TELA Bio, Inc.'s primary business?
TELA Bio, Inc. is in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry, SIC code 3841.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 19, 2024.
What does TELA Bio intend to use the net proceeds for?
The company intends to use the net proceeds for general corporate purposes, including research and development, sales and marketing, and working capital.
Where are TELA Bio's principal executive offices located?
TELA Bio's principal executive offices are located at 1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania 19355.
Filing Stats: 668 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-05-20 16:15:37
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TELA Nasdaq Global Market
Filing Documents
- tm2414892d1_8k.htm (8-K) — 29KB
- tm2414892d1_ex99-1.htm (EX-99.1) — 11KB
- tm2414892d1_ex99-1img001.jpg (GRAPHIC) — 7KB
- 0001104659-24-063416.txt ( ) — 226KB
- tela-20240519.xsd (EX-101.SCH) — 3KB
- tela-20240519_lab.xml (EX-101.LAB) — 33KB
- tela-20240519_pre.xml (EX-101.PRE) — 22KB
- tm2414892d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On May 20, 2024, TELA Bio, Inc. (the " Company ") issued a press release announcing the appointment of Greg Firestone as its Chief Commercial Officer, effective as of May 20, 2024. Mr. Firestone first joined the Company in October 2017 and has served most recently as the Company's Chief Business Officer, where he has led the Company's strategic customer relations team. He has over 35 years of experience in the acute and non-acute healthcare sectors, with much of his tenure in strategy and partnership development, stakeholder collaboration, and strategic consulting initiatives. Throughout his career, Mr. Firestone has worked closely with integrated delivery networks (" IDNs "), health systems, group purchasing organizations, and suppliers, developing deep relationships throughout the MedTech landscape. Prior to his tenure with the Company, he held several executive and sales leadership roles in medical device, GPO and logistics, including as founder and CEO of Dermal Life, LLC, co-founder and president of Mossberg Labs, and owner and CEO of NCI, where Mr. Firestone founded the IDN Summit & Expo, and authored Swimming with the Supertankers , a book written to assist supplier sales and marketing professionals. A copy of this press release is filed as Exhibit 99.1 hereto and incorporated herein by reference. On May 19, 2024, Peter Murphy, the Company's current Chief Commercial Officer, was terminated without Cause (as such term is defined in Mr. Murphy's employment agreement) from the Company, effective immediately. Mr. Murphy will receive a severance package in accordance with the terms of his employment agreement. The Company extends its deepest gratitude to Mr. Murphy for his lasting contributions to the Company. Item 9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release of TELA Bio, Inc., dated May 20, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELA BIO, INC. By: /s/ Antony Koblish Name: Antony Koblish Title: President, Chief Executive Officer and Director Date: May 20, 2024